A pediatric prognostic score for patients undergoing allogeneic hematopoietic stem cell transplantation

被引:7
作者
Arndt, Clemens [1 ]
Beck, James F. [1 ]
Gruhn, Bernd [1 ]
机构
[1] Jena Univ Hosp, Dept Pediat, Sect Hematol & Oncol, D-07740 Jena, Germany
关键词
hematopoietic stem cell transplantation; children; score; serum ferritin; cholinesterase; disease risk; ACUTE-LEUKEMIA; IRON OVERLOAD; MORTALITY TRM; BONE-MARROW; RISK SCORE; CHILDREN; IMPACT; SCT;
D O I
10.1111/ejh.12390
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose: The purpose of this study was to find and evaluate risk factors influencing the outcome of allogeneic hematopoietic stem cell transplantation (HSCT) in children and to develop a score stratifying patients by their risk of mortality. Methods: We retrospectively analyzed the effects of patient and donor characteristics as well as laboratory data including liver, iron, and inflammation parameters on the overall survival of 131 children and young adults with malignant and non-malignant diseases undergoing allogeneic HSCT. Results: In univariate analysis, 5-yr overall survival decreased significantly in patients with high disease risk (38% vs. 74%, P < 0.001), peripheral blood as graft source (47% vs. 73% for bone marrow, P < 0.001), ferritin >1500 ng/mL (41% vs. 79%, P = 0.001), C-reactive protein >10 mg/L (55% vs. 69%, P = 0.019), lactate dehydrogenase >6 mu M.s (22% vs. 67%, P = 0.001), gamma-glutamyl transpeptidase >1 mu M.s (43% vs. 68%, P = 0.035), and cholinesterase < 60 mu M.s (36% vs. 70%, P = 0.002). For HLA recipient-donor match, there was a 5-yr overall survival of 81% for matched related, 58% for matched unrelated, 56% for mismatched unrelated, and 50% for haploidentical related donors (P = 0.020). We subsequently developed a score of parameters significant in multivariate analysis, that is, disease risk (HR = 4.1, P = 0.027), ferritin (HR = 6.4, P = 0.002), and cholinesterase (HR = 5.3, P = 0.027). For this score, 5-yr overall survival was 92% for the low-risk group, 66% for the intermediate-risk group, and 17% for the high-risk group (P < 0.001). Conclusions: Disease risk, ferritin, and cholinesterase are factors decisively influencing the prognosis after HSCT and should be evaluated in further trials.
引用
收藏
页码:509 / 515
页数:7
相关论文
共 50 条
  • [41] Prognostic significance of microRNA-99a in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation
    Cheng, Zhiheng
    Zhou, Lei
    Hu, Kai
    Dai, Yifeng
    Pang, Yifan
    Zhao, Hongmian
    Wu, Sun
    Qin, Tong
    Han, Yu
    Hu, Ning
    Chen, Li
    Wang, Chao
    Zhang, Yijie
    Wu, Depei
    Ke, Xiaoyan
    Shi, Jinlong
    Fu, Lin
    [J]. BONE MARROW TRANSPLANTATION, 2018, 53 (09) : 1089 - 1095
  • [42] Acute kidney injury in pediatric hematopoietic stem cell transplantation patients
    Matbouly, Safa
    Mohamed, Wafaa E. I.
    Nabil, Esraa
    Sallam, Dina E.
    [J]. EGYPTIAN JOURNAL OF HAEMATOLOGY, 2024, 49 (04) : 386 - 391
  • [43] Prevalence of Ototoxicity Following Hematopoietic Stem Cell Transplantation in Pediatric Patients
    Gertson, Kristen
    Hayashi, Susan S.
    Trinkaus, Kathryn
    Wan, Fei
    Hayashi, Roberti.
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (01) : 107 - 113
  • [44] Pulmonary Function Impairment in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation
    Piesiak, Pawel
    Gorczynska, Ewa
    Brzecka, Anna
    Kosacka, Monika
    Jankowska, Renata
    [J]. RESPIRATORY REGULATION - CLINICAL ADVANCES, 2013, 755 : 143 - 148
  • [45] Acute kidney injury and risk factors in pediatric patients undergoing hematopoietic stem cell transplantation
    Avci, Begum
    Bilir, Ozlem Arman
    Ozlu, Sare Gulfem
    Kanbur, Serife Mehtap
    Gokcebay, Dilek Gurlek
    Bozkaya, Ikbal Ok
    Bayrakci, Umut Selda
    Ozbek, Namik Yasar
    [J]. PEDIATRIC NEPHROLOGY, 2024, 39 (07) : 2199 - 2207
  • [46] Early vascular toxicity after pediatric allogeneic hematopoietic stem cell transplantation
    Leimi, Lilli
    Jahnukainen, Kirsi
    Olkinuora, Helena
    Meri, Seppo
    Vettenranta, Kim
    [J]. BONE MARROW TRANSPLANTATION, 2022, 57 (05) : 705 - 711
  • [47] Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Patients with Treatment-Related Myelodysplastic Syndrome or Acute Myelogenous Leukemia
    Kobos, Rachel
    Steinherz, Peter G.
    Kernan, Nancy A.
    Prockop, Susan E.
    Scaradavou, Andromachi
    Small, Trudy N.
    Shukla, Neerav
    Khalaf, Ramzi
    O'Reilly, Richard J.
    Boulad, Farid
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (03) : 473 - 480
  • [48] Analysis of risk factors for hepatic sinusoidal obstruction syndrome following allogeneic hematopoietic stem cell transplantation in pediatric patients
    Kloehn, Jaspar
    Brodt, Grit
    Ernst, Jana
    Gruhn, Bernd
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (06) : 1447 - 1455
  • [49] The Impact of Graft Composition on Clinical Outcomes in Pediatric Patients Undergoing Unmanipulated HLA-Mismatched/Haploidentical Hematopoietic Stem Cell Transplantation
    Liu, Dai-Hong
    Zhao, Xiao-Su
    Chang, Ying-Jun
    Liu, Yan-Kai
    Xu, Lan-Ping
    Chen, Huan
    Han, Wei
    Chen, Yu-Hong
    Wang, Yu
    Huang, Xiao-Jun
    [J]. PEDIATRIC BLOOD & CANCER, 2011, 57 (01) : 135 - 141
  • [50] TCR α+β+/CD19+ cell-depleted hematopoietic stem cell transplantation for pediatric patients
    Mitchell, Richard
    Cole, Theresa
    Shaw, Peter J.
    Mechinaud, Francoise
    O'Brien, Tracey
    Fraser, Chris
    [J]. PEDIATRIC TRANSPLANTATION, 2019, 23 (06)